Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated June 23, 2023, serves as a partial correction to the Notice of Convocation for the 147th Ordinary General Meeting of Shareholders. The document addresses a specific error in the "Reference Document for the General Meeting of Shareholders" regarding the share ownership of the President and Representative Director, Mr. Christophe Weber.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly administrative and does not contain financial performance data.
Material Changes
The material change reported is a correction to the disclosed number of Company Shares owned by Mr. Christophe Weber in the Second Proposal (page 8) of the shareholder meeting materials:
- Before Correction: 378,100 shares
- After Correction: 628,100 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the correction of the shareholding disclosure.
Investor Verification Checklist
- Verify the corrected share ownership count of 628,100 shares for Mr. Christophe Weber in the official shareholder meeting materials.
- Confirm that the correction applies specifically to the Second Proposal on page 8 of the Reference Document.
- Note that this filing contains no financial results or operational updates for the period.